Tigenix

Tigenix_Logo.jpg

Contact information

Tigenix, SAU
María Pascual, VP of Regulatory Affairs and Corporate QA
Marconi, 1. Parque Tecnológico de Madrid
Tres Cantos
Madrid
918049264
918049263
Areas of activities
  • A. Health Biotechnology
    • Areas of activity
      • Biodrugs
      • Stem cells
      • Cellular Therapy
    • Therapeutic areas
      • Dermatology
      • Musculoskeletal system
      • Inflammatory diseases
      • Immunology
      • Digestive system and hepatology
  • C. Industrial Biotechnology
    • Cell lines

TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with one marketed product, ChondroCelect, and a strong clinical stage pipeline of adult stem cell programs. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain) and Sittard-Geleen (the Netherlands).

Products and services

The company?s lead product, ChondroCelect, for cartilage repair in the knee, is the only approved cell-based product in Europe, and is currently being launched across Europe. TiGenix?s adipose derived allogeneic stem cell platform has been extensively validated: Cx601, Phase III clinical trial to treat complex perianal fistula in patients with Crohn?s, a Phase IIa trial in rheumatoid arthritis ongoing, and a Phase I trial to investigate intra-lymphatic administration in autoimmune disorders.